Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing ...

Cardiac Dimensions, a Kirkland, Wash., company with a technology to treat heart valve malfunction, has raised $53 million ...

Cardiac Dimensions has secured $53m in a Series E funding round to support its ongoing pivotal trial assessing the company’s ...

CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Gearing Up for Phase 3 Trial of Tecarfarin Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a biopharmaceutical company developing tecarfarin, a ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve ...

A novel therapeutic showed significant promise in slowing aortic valve calcification, potentially extending time until or eliminating need for transcatheter or surgical intervention for stenosis, ...

6-month-old Struthers' baby Ariella Torres received her third open heart surgery Monday in Cincinnati. The parents of Ariella ...

According to doctors, the condition can lead to the thickening of your heart muscle, left ventricular stiffness, mitral valve changes, and cellular changes, all of which can be life-threatening.